Summary
This cost-effectiveness analysis, based on a randomised controlled trial of 251 patients with severe ischaemic mitral regurgitation, found minimal differences in costs and quality-adjusted life years between mitral valve repair and replacement over 2 years. Over longer time horizons (10 years), replacement showed a small uncertain cost-effectiveness advantage due to lower cardiovascular readmission rates, though survival benefit was minimal and cost differences remained statistically uncertain.
UK applicability
This analysis is based on US hospital cost data and healthcare system structures; direct applicability to UK practice would require adjustment for National Health Service cost structures, surgical capacity, and patient pathways, though the clinical trial outcomes and comparative effectiveness patterns may be informative.
Key measures
In-hospital costs, 2-year cumulative costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, cardiovascular readmission rates, survival
Outcomes reported
The study compared costs, quality-adjusted life years (QALYs), cardiovascular readmission rates, and survival outcomes between mitral valve repair and replacement strategies over 2, 5, and 10-year time horizons.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.